Loading…

AVITA Medical IncRCELCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 100
Mkt cap
$529M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$9.83M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 14.5%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$16.83
1D+6.7%
1W-2.7%
1M+22.0%
3M+66.8%
6M+289.6%
YTD+387.8%
1Y+336.0%
ATR %7.2%
Beta1.60
52w lowhigh8.7% off high

What AVITA Medical does

Employees: 226

AVITA Medical at a glance

Size AVITA Medical (RCEL) is a United States Health Care company (Medical Specialties) with a market value of $529M, the 2638th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.83 on 18 Nov 2026.

Performance Over six months the shares gained 289.6%, against -23.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 17.0% over the last twelve months (peer median +5.1%); the operating margin is -33.9% (peer median 2.5%).

Valuation It trades at 6.7× enterprise value to sales against a peer median of 3.0× (4th most expensive of 19).

Backlog Backlog (remaining performance obligations) was $300,000 at 30 Sep 2026, flat on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10020030040021 May 202621 Aug 202618 Nov 2026RCEL 376Peer median 78
Six months, rebased to 100: AVITA Medical against the median of its 20 peers (local-currency closes).

AVITA Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$84.7M$71.6M$64.3M$50.1M$34.4M
Revenue growth—+11%+28%+46%—
Gross profit$69.7M$58.8M$55.2M$42.4M$28.4M
EBITDA-$26.2M-$39.6M-$55.4M-$121M-$29.2M
Net income-$36.1M-$48.6M-$61.8M-$35.4M-$26.7M
Free cash flow-$19.3M-$32.2M-$58.1M-$39.4M-$19.5M
Capital expenditure-$379,421$1.10M$9.33M$1.45M$525,000
Total debt$47.1M$46.0M$46.0M$42.4M$918,000

Quarterly statements and history in the cockpit →

AVITA Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%MYGNZJYL300439NNNN6053693008693006397979AVR688075688580301235MEDXPACB300952002932RCEL6-month return →1-month return →
Up and to the right = strong over both horizons. AVITA Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×50×100×MYGNZJYL3004396053693008697979AVR688075688298603122301235PACBRCELRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AVITA Medical is the large dot.

AVITA Medical competitors and peer comparison

How AVITA Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AVITA Medical against its 20 peers (data as of 18 Nov 2026)
MeasureRCELPeer medianRank in peer set
1-month return+22.0%-6.7%2nd highest of 21
6-month return+289.6%-23.4%highest of 21
Distance from 52-week high-8.7%-44.6%2nd highest of 21
Revenue growth (TTM)+17.0%+5.1%3rd highest of 21
Operating margin-33.9%2.5%5th lowest of 21
EV / Sales6.7×3.0×4th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%

AVITA Medical backlog

AVITA Medical reported $300,000 of remaining performance obligations at 30 Sep 2026, flat from a year earlier and flat from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Which companies are AVITA Medical's closest peers?
The cockpit's peer set: Myriad Genetics (MYGN), Jin Medical International (ZJYL), MedicalSystem Biotechnology (300439.SZ), Anbio Biotechnology (NNNN), Zhejiang Gongdong Medical Technology (605369.SS), Contec Medical Systems (300869.SZ), Guangdong Hybribio Biotech (300639.SZ), Shofu (7979.T).
Is AVITA Medical expensive compared with its peers?
On ev / sales it trades at 6.7× against a peer median of 3.0×, 4th most expensive of 19 in its peer set.
How has AVITA Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +289.6% against -23.4% for the median peer; over one year +336.0%.
What is AVITA Medical's backlog?
AVITA Medical's remaining performance obligations (contracted revenue not yet recognised) were $300,000 at 30 Sep 2026, 0% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.